SIREN : 453099517
PHARMACOM is a French company founded 22 years ago, specialized in the sector Programmation informatique. Based in ARTIGUES-PRES-BORDEAUX (33370), this company of category PME shows in 2024 a revenue of 12.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12 881 308 € | N/C | 10 408 949 € | N/C | N/C | N/C | N/C | N/C | 5 702 248 € |
| Net income | 1 674 554 € | 1 287 071 € | 1 104 534 € | 1 100 306 € | 828 576 € | 625 179 € | 393 421 € | 216 334 € | 167 613 € |
| EBITDA | 2 319 082 € | N/C | 1 563 165 € | N/C | N/C | N/C | N/C | N/C | 241 463 € |
| Net margin | 13.0% | N/C | 10.6% | N/C | N/C | N/C | N/C | N/C | 2.9% |
In 2024, PHARMACOM achieves revenue of 12.9 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +10.7%. After deducting consumption (5.0 M€), gross margin stands at 7.9 M€, i.e. a rate of 61%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 2.3 M€, representing 18.0% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.7 M€, i.e. 13.0% of revenue. This profit can be retained or distributed to shareholders.
12 881 308 €
7 882 312 €
2 319 082 €
2 235 564 €
1 674 554 €
18.0%
The debt ratio (= Financial debt / Equity x 100) stands at 47%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 45%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.7 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 13.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
46.683%
44.965%
13.638%
0.671
31.7%
In 2024, the debt ratio of PHARMACOM (46.68) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PHARMACOM (45.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of PHARMACOM (0.67) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 257.78. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.4x. Coverage is limited: any activity downturn would jeopardize interest payments.
257.776
1.387
In 2024, the liquidity ratio of PHARMACOM (257.78) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of PHARMACOM (1.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 13 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 36 days. Favorable situation: supplier credit is longer than customer credit by 23 days. Inventory turnover is 25 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 13 days of revenue, i.e. 466 k€ to permanently finance. Over 2016-2024, WCR increased by +112%, requiring additional financing.
465 530 €
13 j
36 j
25 j
13 j
Based on 120 transactions of similar company sales (all years), the value of PHARMACOM is estimated at 4 348 986 € (range 2 025 022€ - 11 650 993€). With an EBITDA of 2 319 082€, the sector multiple of 2.2x is applied. The price/revenue ratio is 0.27x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 120 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMACOM with other companies in the same sector:
Voir toutes les statistiques du secteur Programmation informatique
The revenue of PHARMACOM in 2024 is 12.9 M€.
Yes, PHARMACOM generated a net profit of 1.7 M€ in 2024.
The headquarters of PHARMACOM is located in ARTIGUES-PRES-BORDEAUX (33370), in the department Gironde.
The tax return of PHARMACOM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMACOM operates in the sector Programmation informatique (NAF code 62.01Z). See the 'Sector positioning' section above to compare the company with its competitors.